In a report published Thursday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Equal-Weight rating on Catamaran Corp. CTRX and maintained the $45.00 price target.
In the report, Morgan Stanley noted, “The acquisition of Salveo Specialty Pharmacy marks CTRX's M&A debut since Restat in 8/2013. While estimated EBITDA contribution of ~$20 million is below expectations, the acquisition is aligned with management's strategy of building a specialty franchise and could help build CTRX offering in the fastest growth area in the market.”
Catamaran Corp. closed on Wednesday at $42.56.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in